Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 90

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Venture Financing 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Celator Pharma Secures US$3 Million In Venture Financing 24
Partnerships 25
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Celator Pharma Extends Research Agreement With Cephalon 29
Merger 30
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 30
Licensing Agreements 32
Jazz Pharma Enters into License Agreement with XL-protein 32
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 33
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Jazz Pharma Enters into Licensing Agreement with Pfenex 36
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 39
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 40
Equity Offering 41
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Debt Offering 45
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Asset Transactions 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 47
Aytu BioScience Acquires ProstaScint from Jazz Pharma 48
Essex Bidco Acquires Assets from Jazz Pharma 49
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 51
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 52
Acquisition 54
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 54
Jazz Pharma Acquires Alize Pharma 56
AstraZeneca May Acquire Ariad Pharma 57
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 59
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 61
Jazz Pharmaceuticals Plc - Key Competitors 64
Jazz Pharmaceuticals Plc - Key Employees 65
Jazz Pharmaceuticals Plc - Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Recent Developments 68
Financial Announcements 68
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 68
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 69
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 70
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 72
Aug 09, 2016: Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results 74
May 10, 2016: Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results 76
Feb 23, 2016: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results 77
Corporate Communications 79
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 79
Product News 80
11/07/2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting 80
08/02/2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation 82
03/30/2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update 83
Product Approvals 84
Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow 84
Clinical Trials 85
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 85
Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting 86
Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD 88
Other Significant Developments 89
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90

List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2011 to YTD 2017 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Celator Pharma Secures US$3 Million In Venture Financing 24
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Celator Pharma Extends Research Agreement With Cephalon 29
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 30
Jazz Pharma Enters into License Agreement with XL-protein 32
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 33
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Jazz Pharma Enters into Licensing Agreement with Pfenex 36
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 39
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 40
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 47
Aytu BioScience Acquires ProstaScint from Jazz Pharma 48
Essex Bidco Acquires Assets from Jazz Pharma 49
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 51
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 52
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 54
Jazz Pharma Acquires Alize Pharma 56
AstraZeneca May Acquire Ariad Pharma 57
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 59
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 61
Jazz Pharmaceuticals Plc, Key Competitors 64
Jazz Pharmaceuticals Plc, Key Employees 65
Jazz Pharmaceuticals Plc, Other Locations 66
Jazz Pharmaceuticals Plc, Subsidiaries 66

List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 12

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027